Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888817098Aexternal-prioritypatent/GB8817098D0/en
Priority claimed from GB898904686Aexternal-prioritypatent/GB8904686D0/en
Application filed by Glaxo Group LimitedfiledCriticalGlaxo Group Limited
Priority claimed from YU142789Aexternal-prioritypatent/YU47021B/en
Publication of SI8911427ApublicationCriticalpatent/SI8911427A/en
Publication of SI8911427BpublicationCriticalpatent/SI8911427B/en
PATENTNI ZAHTEVKI 1. Postopek za pripravo soli, tvorjenih med ranitidinom in kompleksom bizmuta s karboksilno kislinp, ali solvata take soli, označen s tem, da obsega reakcijo ranitidina s kompleksom bizmut-karboksilna kislina.A process for the preparation of salts formed between ranitidine and the bismuth complex with carboxylic acid or a solvate of such a salt, characterized in that it comprises the reaction of ranitidine with the bismuth-carboxylic acid complex.2. Postopek po zahtevku 1, označen s tem, da karboksilna kislina vsebuje najmanj tri funkcionalne skupine v molekuli poleg karboksilne skupine, ki tvori soli z ranitidinom.The process according to claim 1, characterized in that the carboxylic acid contains at least three functional groups in the molecule in addition to the carboxyl group which forms salts with ranitidine.3. Postopek po enem od zahtevkov 1-2, označen s tem, da je karboksilna kislina citronska, vinska, etilendiamintetraocetna, propilcitronska ali agaricinska.The process according to one of claims 1 to 2, characterized in that the carboxylic acid is citric, tartaric, ethylenediaminetetraacetic, propylcitronic or agaricinic.4. Postopek po enem od zahtevkov 1-2, označen s tem, da je karboksilna kislina citronska ali vinska.The process according to one of claims 1 to 2, characterized in that the carboxylic acid is citric or vintage.5. Postopek po enem od zahtevkov 1-2, označen s tem, daje karboksilna kislina citronska.The process according to one of claims 1 to 2, characterized in that the carboxylic acid is citric.6. Postopek po zahtevku 1, označen s tem, da dobimo N-[2-[[[5-[(dimetilamino)metil]-2-furanil]metil]tio]etil]-N’-metil-2-nitro- 1.1- etendiamin 2-hidroksi-l,2,3-propantrikarboksilat bizmut(3+) kompleks in njegove solvate.The process according to claim 1, characterized in that N- [2 - [[[5 - [(dimethylamino) methyl] -2-furanyl] methyl] thio] ethyl] -N'-methyl-2-nitro- 1,1-etenediamine 2-hydroxy-1,2,3-propanetricarboxylate bismuth (3+) complex and its solvates.7. Postopek po zahtevku 1, označen s tem, da dobimo N-[2-[[[5-[(dimetilamino)metil]-2-furanil]metil]tio]etil]-N’-metil-2-nitro- 1.1- etendiamin [(R-R*R*)]-2,3-dihidroksibutandioat bizmut(3+) kompleks in njegove solvate. Za GLAXO GROUP LIMITED:The process according to claim 1, characterized in that N- [2 - [[[5 - [(dimethylamino) methyl] -2-furanyl] methyl] thio] ethyl] -N'-methyl-2-nitro- 1,1-etenediamine [(RR * R *)] - 2,3-dihydroxybutanedioate bismuth (3+) complex and its solvates. For GLAXO GROUP LIMITED:
SI8911427A1988-07-181989-07-17Process for obtaining salts of ranitidine with bismuth carboxylic acids complexes
SI8911427B
(en)
Derivatives of 4,5-dihydro-4-oxofuran-2-carboxylic acid, especially for use as hypolipidemic agents, processes for their preparation, pharmaceutical compositions comprising them, tetrahydropyran-2,3,5-triones useful in the preparation of the said derivatives and a process for preparing these tetrahydropyran-2,3,5-triones
(-) - 1BETA-ETHYL-1ALFA-HYDROXYMETHYL-1,2,3,4,6,7,12,12BALFA-OCTAHYDROINDOLO / 2,3-A / QUINOLIZINE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
Pharmaceutical composition in solid unit dosage form adapted for oral administration for treatment of gastrointestinal tract upset comprising ranitidine salt and a bismuth carboxylate and method for its preparation
Substituted 2-phenylamino-imidazoline-(2)derivatives and their acid addition salts,processes for their preparation and pharmaceutical compositions containing these compounds